Medicine – Causes of Diabetes Insipidus

Diabetes insipidus – DI is a disorder of water balance characterised by the production of large volumes of abnormally dilute urine. The resulting excessive urinary water loss produces polyuria and polydipsia, and if the patient cannot replace the lost water, hypernatraemia and dehydration may develop.

The two major forms in the original notes are:

Central DI – reduced secretion of antidiuretic hormone.

Nephrogenic DI – reduced renal response to antidiuretic hormone.

The older term cranial DI is still understood, but central diabetes insipidus is now more commonly used.

1. Normal ADH Physiology

Antidiuretic hormone – ADH, also called:

Arginine vasopressin – AVP,

is synthesised mainly in the:

Supraoptic and paraventricular nuclei of the hypothalamus.

It is transported along axons to the:

Posterior pituitary,

where it is stored and released into the circulation.

2. Action of ADH

ADH acts mainly on:

V₂ receptors

on principal cells of the renal collecting ducts.

This activates signalling that inserts:

Aquaporin-2 water channels

into the luminal membrane.

Therefore:

ADH → V₂ receptor → aquaporin-2 insertion → ↑ water reabsorption → concentrated urine.

3. What Happens in Diabetes Insipidus?

If there is insufficient ADH:

Collecting ducts cannot conserve water effectively.

Alternatively, ADH may be present but the kidneys may fail to respond.

In either situation:

↓ Water reabsorption

↓

Large-volume dilute urine

↓

Polyuria

↓

Thirst and polydipsia

↓

If water intake is inadequate:

Hypernatraemia + increased plasma osmolality + dehydration.

4. Central Diabetes Insipidus

Central DI results from inadequate synthesis or secretion of:

ADH/AVP.

Therefore:

↓ ADH secretion → collecting duct cannot maximally concentrate urine → excessive free-water loss.

The major causes include:

Idiopathic/autoimmune disease.

Pituitary or hypothalamic surgery.

Trauma.

Tumours.

Infiltrative diseases.

Genetic disorders.

5. Idiopathic Central DI

The original notes correctly include:

Idiopathic central DI.

This means no obvious structural cause is identified during the initial evaluation.

Some cases previously classified as idiopathic are now recognised to have:

Autoimmune

or other identifiable mechanisms.

Therefore appropriate follow-up may still be required.

6. Pituitary Surgery

The original notes correctly identify:

Pituitary surgery

as an important cause.

Surgery around the:

Hypothalamus.

Pituitary stalk.

Posterior pituitary.

can disrupt the hypothalamic neurons or axons responsible for ADH transport and release.

Therefore:

PITUITARY/HYPOTHALAMIC SURGERY → ↓ ADH → CENTRAL DI.

7. Postoperative DI

Central DI may appear after surgery involving the pituitary region.

Depending on the degree of injury, it may be:

Transient

or

Permanent.

Patients require careful monitoring of:

Urine output.

Serum sodium.

Fluid balance.

8. Infiltrative Hypothalamic Disease

Infiltrative diseases can damage the:

Hypothalamus

or

Pituitary stalk.

The original notes correctly include:

Sarcoidosis

and

Histiocytosis X.

9. Sarcoidosis

Sarcoidosis can involve the hypothalamic–pituitary region as part of:

Neurosarcoidosis.

Granulomatous infiltration can interfere with ADH production or release.

Therefore:

SARCOIDOSIS → HYPOTHALAMIC/PITUITARY INFILTRATION → CENTRAL DI.

Interestingly, sarcoidosis can also contribute to nephrogenic DI indirectly through hypercalcaemia, which impairs the kidney’s concentrating ability.

10. Histiocytosis X

The older term:

Histiocytosis X

is now generally replaced by:

Langerhans cell histiocytosis – LCH.

LCH can infiltrate the:

Hypothalamic–pituitary axis.

Central DI is an important endocrine manifestation.

Therefore:

LCH + POLYURIA/POLYDIPSIA → CONSIDER CENTRAL DI.

11. Craniopharyngioma

The original notes correctly include:

Craniopharyngioma.

These tumours occur close to the:

Pituitary stalk and hypothalamus.

They may damage the ADH-producing or transporting system.

Therefore central DI may develop either from the:

Tumour itself

or following:

Surgery for the tumour.

12. Other Tumours

Other masses affecting the hypothalamic–pituitary region may also cause central DI.

Examples include selected:

Germ-cell tumours.

Metastases.

Other suprasellar lesions.

The important principle is:

Damage to the hypothalamus or pituitary stalk can impair ADH secretion.

13. Trauma

The original notes correctly include:

Trauma.

Severe head injury may damage the:

Hypothalamus.

Pituitary stalk.

Posterior pituitary pathway.

This can produce:

Transient or permanent central DI.

14. Familial Central DI

Rare genetic disorders can cause central DI.

These may involve abnormalities in:

AVP synthesis or processing.

Some familial forms are inherited in an:

Autosomal dominant pattern.

15. DIDMOAD Syndrome

The original notes correctly identify:

DIDMOAD syndrome.

DIDMOAD stands for:

Diabetes Insipidus.

Diabetes Mellitus.

Optic Atrophy.

Deafness.

This disorder is also known as:

Wolfram syndrome.

16. Wolfram Syndrome

Wolfram syndrome is a rare genetic neurodegenerative disorder, classically associated with:

Juvenile-onset diabetes mellitus.

Optic atrophy.

Central diabetes insipidus.

Sensorineural deafness.

Therefore:

DIDMOAD = DI + DM + OPTIC ATROPHY + DEAFNESS.

This is a useful examination mnemonic.

17. Nephrogenic Diabetes Insipidus

In nephrogenic DI, ADH is produced and released, but the kidneys are:

Resistant to its action.

Therefore:

ADH present

↓

Kidney fails to respond adequately

↓

Aquaporin-mediated water reabsorption impaired

↓

Large-volume dilute urine.

18. Causes of Nephrogenic DI

Nephrogenic DI can be:

Inherited

or

Acquired.

Acquired causes are considerably more common and include:

Lithium.

Hypercalcaemia.

Hypokalaemia.

Kidney disease.

Post-obstructive states.

Other medications can also impair renal concentrating ability.

19. Inherited Nephrogenic DI

The original notes state:

Primary X-linked or dominant.

This requires some refinement.

The most common inherited form is:

X-linked nephrogenic DI

caused by abnormalities in the:

AVPR2 gene, which encodes the renal V₂ vasopressin receptor.

20. Aquaporin-2 Mutations

Other inherited forms are caused by mutations involving:

Aquaporin-2 – AQP2.

These can be:

Autosomal recessive

or, less commonly:

Autosomal dominant.

Therefore the inheritance pattern depends on the molecular defect.

21. Hypercalcaemia

The original notes correctly identify:

Hypercalcaemia

as a cause of nephrogenic DI.

Persistent high calcium interferes with the kidney’s ability to:

Concentrate urine.

It impairs responsiveness of the collecting duct to ADH and can affect the medullary concentration gradient.

Therefore:

HYPERCALCAEMIA → IMPAIRED URINARY CONCENTRATION → POLYURIA → NEPHROGENIC DI.

22. Hypokalaemia

The original notes also correctly include:

Hypokalaemia.

Persistent potassium deficiency reduces the kidney’s ability to concentrate urine and can impair:

Aquaporin-2 expression and collecting-duct responsiveness.

Therefore:

HYPOKALAEMIA → ADH RESISTANCE/IMPAIRED CONCENTRATION → NEPHROGENIC DI.

23. Chronic Kidney Disease and Tubulointerstitial Disease

Several forms of renal disease impair the kidney’s concentrating ability.

The original notes include:

Chronic pyelonephritis.

Adult polycystic kidney disease.

Post-urinary obstruction.

These can produce a nephrogenic DI-like concentrating defect.

24. Chronic Pyelonephritis

Chronic tubulointerstitial injury can damage the structures required to maintain:

The renal medullary concentration gradient.

As a result, the kidney becomes less capable of concentrating urine even when ADH is present.

Therefore:

CHRONIC TUBULOINTERSTITIAL DAMAGE → IMPAIRED CONCENTRATING ABILITY → POLYURIA.

25. ADPKD

The older term:

Adult polycystic kidney disease

is better expressed as:

Autosomal dominant polycystic kidney disease – ADPKD.

Structural disruption of the renal medulla can impair urinary concentrating ability.

Patients may therefore develop:

Polyuria and nocturia, particularly as renal disease progresses.

26. Post-Urinary Obstruction

The original notes correctly include:

Post-urinary obstruction.

After relief of significant urinary obstruction, patients may develop:

Post-obstructive diuresis.

Tubular dysfunction and reduced responsiveness to ADH may contribute to very large urine volumes.

This can cause substantial losses of:

Water and electrolytes.

27. Lithium

The original notes correctly identify:

Lithium

as a major drug cause of nephrogenic DI.

This is one of the most important acquired causes.

Lithium enters collecting-duct principal cells and interferes with:

ADH signalling

and

Aquaporin-2 expression/function.

Therefore:

LITHIUM → COLLECTING-DUCT ADH RESISTANCE → NEPHROGENIC DI.

28. Clinical Importance of Lithium

Patients taking chronic lithium therapy may develop:

Polyuria.

Polydipsia.

Impaired urinary concentrating ability.

The concentrating defect can sometimes persist even after lithium is discontinued, particularly after prolonged exposure.

29. Demeclocycline

The original notes correctly include:

Demeclocycline.

Demeclocycline reduces renal responsiveness to:

ADH.

It can therefore intentionally produce a form of:

Nephrogenic DI.

Historically, this effect has been used in selected patients with:

SIADH.

Its use is now more limited because of concerns such as:

Nephrotoxicity and the availability of other approaches.

30. Glibenclamide – Important Correction

The original notes include:

Glibenclamide

as a cause of nephrogenic DI.

This is not a standard modern cause of nephrogenic diabetes insipidus and should not be memorised as one of the major drug associations.

The high-yield drug causes are much more importantly:

Lithium.

Demeclocycline.

Other recognised drug-related causes include selected nephrotoxic agents that impair tubular function.

31. Sarcoidosis and Nephrogenic DI

The original notes also list:

Sarcoidosis

under nephrogenic DI.

This can occur indirectly because sarcoidosis may produce:

Hypercalcaemia.

Hypercalcaemia then impairs the renal response to ADH.

Therefore sarcoidosis can potentially contribute to DI by two different mechanisms:

Hypothalamic/pituitary involvement → central DI.

or

Hypercalcaemia → nephrogenic DI.

32. Clinical Features of DI

The characteristic symptoms are:

Polyuria.

Polydipsia.

Nocturia.

The urine is:

Dilute.

Patients often develop a strong preference for:

Cold water.

33. Hypernatraemia

If thirst is intact and water is freely available, patients can often compensate for urinary losses by drinking large quantities of water.

Therefore serum sodium may remain:

Normal.

However, if the patient cannot obtain enough water:

Free-water loss exceeds intake

↓

Serum Na⁺ rises

↓

Plasma osmolality rises

↓

Hypernatraemic dehydration develops.

34. When DI Becomes Particularly Dangerous

DI becomes especially dangerous in patients who:

Cannot communicate thirst.

Cannot access water.

Are unconscious.

Are very young.

Have neurological impairment.

These patients can develop severe:

Hypernatraemia and dehydration.

35. Diagnosis

The first step is to establish that the patient truly has:

Hypotonic polyuria.

This requires distinguishing DI from other causes of frequent or excessive urination.

Important measurements include:

24-hour urine volume.

Urine osmolality.

Serum sodium.

Plasma osmolality.

Glucose.

Calcium.

Potassium.

Renal function.

36. Exclude Osmotic Diuresis

A major differential diagnosis is:

Diabetes mellitus.

In uncontrolled diabetes mellitus:

Glucose spills into urine

↓

Water follows glucose

↓

Osmotic diuresis

↓

Polyuria.

The urine in diabetes mellitus may therefore have a relatively high osmolality because of:

Glucose.

In DI, the urine is characteristically:

Inappropriately dilute.

37. Primary Polydipsia

Another important differential is:

Primary polydipsia.

Here the primary problem is:

Excessive water intake

rather than failure of ADH production or action.

Excess water intake suppresses ADH and produces:

Dilute urine.

Therefore distinguishing primary polydipsia from partial DI can sometimes be challenging.

38. Water-Deprivation Testing

Traditionally, selected patients were investigated using a supervised:

Water-deprivation test.

The principle is to determine whether the kidney can appropriately concentrate urine when water is withheld.

In healthy physiology:

Water deprivation → ↑ ADH → concentrated urine.

In DI:

Urine remains inappropriately dilute.

Because dehydration can become dangerous, this test requires:

Careful specialist supervision.

39. Desmopressin Response

Desmopressin – DDAVP is an ADH analogue.

After desmopressin:

Central DI → urine concentration rises substantially, because the missing hormone has been replaced.

In:

Nephrogenic DI → little or no appropriate response, because the kidney remains resistant to ADH.

Partial forms may show intermediate responses.

40. Copeptin – Modern Diagnostic Addition

Modern specialist evaluation may use:

Copeptin.

Copeptin is released with endogenous vasopressin and is easier to measure reliably than ADH itself.

Stimulated copeptin-based testing can help distinguish:

Central DI.

Nephrogenic DI.

Primary polydipsia.

This is increasingly important in specialist diagnostic pathways.

41. Treatment of Central DI

The major treatment for established central DI is:

Desmopressin – DDAVP.

It acts mainly at renal:

V₂ receptors

and increases collecting-duct water reabsorption.

Therefore:

DESMOPRESSIN → ↑ WATER REABSORPTION → ↓ URINE VOLUME.

42. Desmopressin Safety

Excessive desmopressin combined with excessive water intake can cause:

Water retention

and

Hyponatraemia.

Therefore therapy requires appropriate monitoring and patient education.

The underlying cause of central DI should also be treated when possible.

43. Treatment of Nephrogenic DI

Treatment begins by correcting the cause.

Examples include:

Correct hypercalcaemia.

Correct hypokalaemia.

Review or stop lithium when clinically appropriate.

Treat underlying renal disease.

Adequate access to water is essential.

44. Thiazides in Nephrogenic DI

Paradoxically:

Thiazide diuretics

can reduce urine volume in nephrogenic DI.

They cause mild volume contraction, increasing proximal sodium and water reabsorption.

Therefore less fluid reaches the distal nephron.

The result is:

Reduced urine volume.

45. Amiloride and Lithium-Induced DI

In lithium-induced nephrogenic DI:

Amiloride

can be particularly useful because it blocks:

ENaC

and reduces lithium entry into collecting-duct principal cells.

Therefore:

LITHIUM-INDUCED DI → CONSIDER AMILORIDE.

46. Central DI – Note Form

CENTRAL DI = TOO LITTLE ADH.

Idiopathic/autoimmune.

Pituitary/hypothalamic surgery.

Trauma.

Infiltrative disease:

Sarcoidosis.

Langerhans cell histiocytosis.

Tumours:

Craniopharyngioma.

Other hypothalamic/pituitary stalk lesions.

Genetic:

Familial central DI.

Wolfram syndrome – DIDMOAD.

47. Nephrogenic DI – Note Form

NEPHROGENIC DI = ADH PRESENT BUT KIDNEY DOES NOT RESPOND PROPERLY.

Inherited:

X-linked AVPR2 mutations.

AQP2 mutations – usually AR, sometimes AD.

Electrolytes:

Hypercalcaemia.

Hypokalaemia.

Renal disease:

Chronic tubulointerstitial disease/chronic pyelonephritis.

ADPKD with concentrating defect.

Post-obstructive state.

Drugs:

Lithium – particularly important.

Demeclocycline.

Other causes of significant tubular injury.

Sarcoidosis:

Can cause nephrogenic concentrating impairment indirectly through:

Hypercalcaemia.

48. Central Versus Nephrogenic DI – Copyable Comparison

CENTRAL DI

Problem:

↓ ADH secretion.

Site of defect:

Hypothalamus/posterior pituitary pathway.

Desmopressin:

Urine concentrating response present, especially in complete central DI.

Typical causes:

Surgery, trauma, craniopharyngioma, sarcoidosis, LCH, idiopathic/autoimmune and genetic disease.

NEPHROGENIC DI

Problem:

↓ renal response to ADH.

Site of defect:

Kidney/collecting duct.

Desmopressin:

Little or no response in complete nephrogenic DI.

Typical causes:

Lithium, hypercalcaemia, hypokalaemia, renal tubular disease and inherited AVPR2/AQP2 abnormalities.

49. Important Clarifications to the Original Notes

The term:

“Cranial DI”

is valid historically, but:

Central diabetes insipidus

is the more commonly used modern term.

ADH is:

Synthesised in the hypothalamus

and then:

Transported to and released from the posterior pituitary.

Therefore central DI may result from damage anywhere along this pathway.

The older term:

Histiocytosis X

should generally be replaced by:

Langerhans cell histiocytosis.

The original inherited nephrogenic DI description of:

“X-linked or dominant”

needs refinement:

AVPR2 mutations → usually X-linked.

AQP2 mutations → usually autosomal recessive, occasionally autosomal dominant.

The original inclusion of:

Glibenclamide

as a major drug cause is outdated and should not be prioritised.

The major examination drug association is:

LITHIUM → NEPHROGENIC DI.

Key Clinical Pattern

For rapid recall:

DI → POLYURIA + POLYDIPSIA + LARGE VOLUMES OF DILUTE URINE.

CENTRAL DI = NOT ENOUGH ADH.

Think:

PITUITARY SURGERY.

HEAD TRAUMA.

CRANIOPHARYNGIOMA.

SARCOIDOSIS.

LANGERHANS CELL HISTIOCYTOSIS.

WOLFRAM/DIDMOAD.

NEPHROGENIC DI = KIDNEYS DO NOT RESPOND TO ADH.

Think:

LITHIUM.

HYPERCALCAEMIA.

HYPOKALAEMIA.

RENAL TUBULAR/CHRONIC KIDNEY DISEASE.

AVPR2/AQP2 MUTATIONS.

And remember the classic treatment distinction:

CENTRAL DI → DESMOPRESSIN.

NEPHROGENIC DI → CORRECT CAUSE ± THIAZIDE; AMILORIDE PARTICULARLY USEFUL FOR LITHIUM-INDUCED DI.